Egis Favipiravir Drug Licenced For Covid-19 Treatment

  • 21 Dec 2020 10:01 AM
  • Hungary Matters
Egis Favipiravir Drug Licenced For Covid-19 Treatment
A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI), the institute said on Saturday.

The licence was issued in an expedited procedure.

The drug, which Egis started developing in April, could be used to treat coronavirus patients from mid-January.

Favipiravir is the second drug, after remdesivir, that has been licenced by the OGYÉI to treat Covid-19 patients.

Photo - for illustration purposes only: MTI

Related links

Manufacture Of Covid Drug Remdesivir Under Way In Hungary

Pfizer’s Vaccine Will Be First Product Used For Mass Covid Vaccination In Hungary

  • How does this content make you feel?

XpatLoop Media Partner

Hungary Matters

Launched in January 2014, this twice-daily newsletter covers 'everything you need to know about what’s going on in Hungary and beyond', according to its publisher the state media agency MTI. Click the title above for more info, and to subscribe.

Explore More Reports